Safety of inhaled nitric oxide after lung transplantation

David N. Cornfield, Carlos E. Milla, Imad Y. Haddad, Joel E. Barbato, Soon J. Park

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The present study tests the hypothesis that therapy with inhaled nitric oxide (iNO) at the time of lung transplantation in patients undergoing bilateral single lung transplantation: (i) is safe; and (ii) does not increase either the duration of mechanical ventilation or the incidence of acute graft dysfunction. Methods: We conducted a prospective, non-randomized trial of iNO at 20 parts per million. The treatment group was comprised of 14 patients (10 females, 4 males) undergoing lung transplantation to address severe end-stage lung disease and pulmonary hypertension (mean pulmonary artery pressure > 30 mmHg). Clinical and histologic parameters were compared with 22 historical control subjects who were matched with the study population for age, diagnosis and disease severity (17 females, 5 males) and had undergone lung transplantation in the preceding 2-year time period. No significant differences were noted between the 2 study groups at baseline. Results: No toxic effect of iNO treatment was evident. Although the incidence of acute graft dysfunction was the same in both groups, the occurrence of acute graft rejection in the initial 4 weeks after transplant was less frequent in the iNO group than in the control group (7% vs 32%, p = 0.05). Fifty percent of the treatment group, as compared with 22% of the control group, were discharged from the hospital within 2 weeks of the procedure (p = 0.05). Conclusions: Early initiation of iNO in lung transplant patients with pulmonary hypertension is safe and may decrease the incidence of acute graft rejection. We speculate that iNO may exert an immunomodulatory effect.

Original languageEnglish (US)
Pages (from-to)903-907
Number of pages5
JournalJournal of Heart and Lung Transplantation
Volume22
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Lung Transplantation
Nitric Oxide
Safety
Transplants
Graft Rejection
Pulmonary Hypertension
Incidence
Control Groups
Poisons
Therapeutics
Artificial Respiration
Pulmonary Artery
Lung Diseases
Pressure
Lung
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Cornfield, D. N., Milla, C. E., Haddad, I. Y., Barbato, J. E., & Park, S. J. (2003). Safety of inhaled nitric oxide after lung transplantation. Journal of Heart and Lung Transplantation, 22(8), 903-907. https://doi.org/10.1016/S1053-2498(02)00809-4

Safety of inhaled nitric oxide after lung transplantation. / Cornfield, David N.; Milla, Carlos E.; Haddad, Imad Y.; Barbato, Joel E.; Park, Soon J.

In: Journal of Heart and Lung Transplantation, Vol. 22, No. 8, 01.08.2003, p. 903-907.

Research output: Contribution to journalArticle

Cornfield, DN, Milla, CE, Haddad, IY, Barbato, JE & Park, SJ 2003, 'Safety of inhaled nitric oxide after lung transplantation', Journal of Heart and Lung Transplantation, vol. 22, no. 8, pp. 903-907. https://doi.org/10.1016/S1053-2498(02)00809-4
Cornfield, David N. ; Milla, Carlos E. ; Haddad, Imad Y. ; Barbato, Joel E. ; Park, Soon J. / Safety of inhaled nitric oxide after lung transplantation. In: Journal of Heart and Lung Transplantation. 2003 ; Vol. 22, No. 8. pp. 903-907.
@article{14c8cd664f13461889d63317ea01a0c0,
title = "Safety of inhaled nitric oxide after lung transplantation",
abstract = "Background: The present study tests the hypothesis that therapy with inhaled nitric oxide (iNO) at the time of lung transplantation in patients undergoing bilateral single lung transplantation: (i) is safe; and (ii) does not increase either the duration of mechanical ventilation or the incidence of acute graft dysfunction. Methods: We conducted a prospective, non-randomized trial of iNO at 20 parts per million. The treatment group was comprised of 14 patients (10 females, 4 males) undergoing lung transplantation to address severe end-stage lung disease and pulmonary hypertension (mean pulmonary artery pressure > 30 mmHg). Clinical and histologic parameters were compared with 22 historical control subjects who were matched with the study population for age, diagnosis and disease severity (17 females, 5 males) and had undergone lung transplantation in the preceding 2-year time period. No significant differences were noted between the 2 study groups at baseline. Results: No toxic effect of iNO treatment was evident. Although the incidence of acute graft dysfunction was the same in both groups, the occurrence of acute graft rejection in the initial 4 weeks after transplant was less frequent in the iNO group than in the control group (7{\%} vs 32{\%}, p = 0.05). Fifty percent of the treatment group, as compared with 22{\%} of the control group, were discharged from the hospital within 2 weeks of the procedure (p = 0.05). Conclusions: Early initiation of iNO in lung transplant patients with pulmonary hypertension is safe and may decrease the incidence of acute graft rejection. We speculate that iNO may exert an immunomodulatory effect.",
author = "Cornfield, {David N.} and Milla, {Carlos E.} and Haddad, {Imad Y.} and Barbato, {Joel E.} and Park, {Soon J.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1053-2498(02)00809-4",
language = "English (US)",
volume = "22",
pages = "903--907",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Safety of inhaled nitric oxide after lung transplantation

AU - Cornfield, David N.

AU - Milla, Carlos E.

AU - Haddad, Imad Y.

AU - Barbato, Joel E.

AU - Park, Soon J.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The present study tests the hypothesis that therapy with inhaled nitric oxide (iNO) at the time of lung transplantation in patients undergoing bilateral single lung transplantation: (i) is safe; and (ii) does not increase either the duration of mechanical ventilation or the incidence of acute graft dysfunction. Methods: We conducted a prospective, non-randomized trial of iNO at 20 parts per million. The treatment group was comprised of 14 patients (10 females, 4 males) undergoing lung transplantation to address severe end-stage lung disease and pulmonary hypertension (mean pulmonary artery pressure > 30 mmHg). Clinical and histologic parameters were compared with 22 historical control subjects who were matched with the study population for age, diagnosis and disease severity (17 females, 5 males) and had undergone lung transplantation in the preceding 2-year time period. No significant differences were noted between the 2 study groups at baseline. Results: No toxic effect of iNO treatment was evident. Although the incidence of acute graft dysfunction was the same in both groups, the occurrence of acute graft rejection in the initial 4 weeks after transplant was less frequent in the iNO group than in the control group (7% vs 32%, p = 0.05). Fifty percent of the treatment group, as compared with 22% of the control group, were discharged from the hospital within 2 weeks of the procedure (p = 0.05). Conclusions: Early initiation of iNO in lung transplant patients with pulmonary hypertension is safe and may decrease the incidence of acute graft rejection. We speculate that iNO may exert an immunomodulatory effect.

AB - Background: The present study tests the hypothesis that therapy with inhaled nitric oxide (iNO) at the time of lung transplantation in patients undergoing bilateral single lung transplantation: (i) is safe; and (ii) does not increase either the duration of mechanical ventilation or the incidence of acute graft dysfunction. Methods: We conducted a prospective, non-randomized trial of iNO at 20 parts per million. The treatment group was comprised of 14 patients (10 females, 4 males) undergoing lung transplantation to address severe end-stage lung disease and pulmonary hypertension (mean pulmonary artery pressure > 30 mmHg). Clinical and histologic parameters were compared with 22 historical control subjects who were matched with the study population for age, diagnosis and disease severity (17 females, 5 males) and had undergone lung transplantation in the preceding 2-year time period. No significant differences were noted between the 2 study groups at baseline. Results: No toxic effect of iNO treatment was evident. Although the incidence of acute graft dysfunction was the same in both groups, the occurrence of acute graft rejection in the initial 4 weeks after transplant was less frequent in the iNO group than in the control group (7% vs 32%, p = 0.05). Fifty percent of the treatment group, as compared with 22% of the control group, were discharged from the hospital within 2 weeks of the procedure (p = 0.05). Conclusions: Early initiation of iNO in lung transplant patients with pulmonary hypertension is safe and may decrease the incidence of acute graft rejection. We speculate that iNO may exert an immunomodulatory effect.

UR - http://www.scopus.com/inward/record.url?scp=0043167794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043167794&partnerID=8YFLogxK

U2 - 10.1016/S1053-2498(02)00809-4

DO - 10.1016/S1053-2498(02)00809-4

M3 - Article

C2 - 12909471

AN - SCOPUS:0043167794

VL - 22

SP - 903

EP - 907

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 8

ER -